Open AccessChimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis
Author(s) -
J. Sridhar,
P. L. K. Desylva,
Yogendra Singh
Publication year - 2006
Publication title -
indian journal of dermatology, venereology, and leprology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.514
H-Index - 45
eISSN - 0973-3922
pISSN - 0378-6323
DOI - 10.4103/0378-6323.25639
Subject(s) - infliximab , psoriasis , medicine , tumor necrosis factor alpha , monoclonal antibody , pathogenesis , adverse effect , gastroenterology , immunology , monoclonal , antibody
Insights into the pathogenesis of psoriasis have provided opportunities to target key steps in the disease process. Tumor necrosis factor-alpha (TNF- alpha) being crucial to the pathogenesis of psoriasis, monoclonal antibodies against this cytokine have proved useful in its treatment.